Induction of lncRNA NORAD accounts for hypoxia-induced chemoresistance and vasculogenic mimicry in colorectal cancer by sponging the miR-495-3p/ hypoxia-inducible factor-1α (HIF-1α)

References

• Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. Lancet. 2019;394:1467–1480.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
   PubMed Web of Science ®Google Scholar
• Mauri G, Sartore-Bianchi A, Russo AG, et al. Early-onset colorectal cancer in young individuals. Mol Oncol. 2019;13:109–131.
   PubMed Web of Science ®Google Scholar
• Dy GK, Hobday TJ, Nelson G, et al. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. Clin Colorectal Cancer. 2009;8:88–93.
   Web of Science ®Google Scholar
• Jing X, Yang F, Shao C, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18:157.
   PubMed Web of Science ®Google Scholar
• Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11:393–410.
   PubMed Web of Science ®Google Scholar
• Wei X, Chen Y, Jiang X, et al. Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments. Mol Cancer. 2021;20:7.
   PubMed Web of Science ®Google Scholar
• Choudhry H, Harris AL. Advances in Hypoxia-Inducible Factor Biology. Cell Metab. 2018;27:281–298.
   PubMed Web of Science ®Google Scholar
• Zhou QY, Tu CY, Shao CX, et al. GC7 blocks epithelial-mesenchymal transition and reverses hypoxia-induced chemotherapy resistance in hepatocellular carcinoma cells. Am J Transl Res. 2017;9:2608–2617.
   PubMed Web of Science ®Google Scholar
• Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77:3965–3981.
   PubMed Web of Science ®Google Scholar
• Wang L, Cho KB, Li Y, et al. Long noncoding RNA (lncRNA)-mediated competing endogenous RNA networks provide novel potential biomarkers and therapeutic targets for colorectal cancer. Int J Mol Sci. 2019;20:5758.
   PubMed Web of Science ®Google Scholar
• Lee S, Kopp F, C CT, et al. Noncoding RNA NORAD regulates genomic stability by sequestering PUMILIO proteins. Cell. 2016;164:69–80.
   PubMed Web of Science ®Google Scholar
• Munschauer M, Nguyen CT, Sirokman K, et al. The NORAD lncRNA assembles a topoisomerase complex critical for genome stability. Nature. 2018;561:132–136.
   PubMed Web of Science ®Google Scholar
• Han T, Wu Y, Hu X, et al. NORAD orchestrates endometrial cancer progression by sequestering FUBP1 nuclear localization to promote cell apoptosis. Cell Death Dis. 2020;11:473.
   PubMed Web of Science ®Google Scholar
• Wang L, Du L, Duan W, et al. Overexpression of long noncoding RNA NORAD in colorectal cancer associates with tumor progression. Onco Targets Ther. 2018;11:6757–6766.
   PubMed Web of Science ®Google Scholar
• Huang Q, Xing S, Peng A, et al. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis. Biosci Rep. 2020;40:BSR20193489.
   PubMed Web of Science ®Google Scholar
• Li H, Wang X, Wen C, et al. Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer. Mol Cancer. 2017;16:169.
   PubMed Web of Science ®Google Scholar
• Zhao X, Wei X, Wang X, et al. Long noncoding RNA NORAD regulates angiogenesis of human umbilical vein endothelial cells via miR5903p under hypoxic conditions. Mol Med Rep. 2020;21:2560–2570.
   PubMed Web of Science ®Google Scholar
• Chen F, Liu L, Wang S. Long non-coding RNA NORAD exhaustion represses prostate cancer progression through inhibiting TRIP13 expression via competitively binding to miR-495-3p. Cancer Cell Int. 2020;20:323.
   PubMed Web of Science ®Google Scholar
• Yan L, Yao J, Qiu J. miRNA-495 suppresses proliferation and migration of colorectal cancer cells by targeting FAM83D. Biomed Pharmacother. 2017;96:974–981.
   PubMed Web of Science ®Google Scholar
• Du B, Wang T, Yang X, et al. SOX9, miR-495, miR-590-3p, and miR-320d were identified as chemoradiotherapy-sensitive genes and miRNAs in colorectal cancer patients based on a microarray dataset. Neoplasma. 2019;66:8–19.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–408.
   PubMed Web of Science ®Google Scholar
• Shaker OG, Ali MA, Ahmed TI, et al. Association between LINC00657 and miR-106a serum expression levels and susceptibility to colorectal cancer, adenomatous polyposis, and ulcerative colitis in Egyptian population. IUBMB Life. 2019;71:1322–1335.
   PubMed Web of Science ®Google Scholar
• Xu K, Zhan Y, Yuan Z, et al. Hypoxia Induces Drug Resistance in Colorectal Cancer through the HIF-1alpha/miR-338-5p/IL-6 Feedback Loop. Mol Ther. 2019;27:1810–1824.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li XY, Hu P, et al. LncRNA NORAD contributes to colorectal cancer progression by inhibition of miR-202-5p. Oncol Res. 2018;26:1411–1418.
   PubMed Web of Science ®Google Scholar
• Zhao L, Liu C, Yan S, et al. LINC00657 promotes colorectal cancer stem-like cell invasion by functioning as a miR-203a sponge. Biochem Biophys Res Commun. 2020;529:500–506.
   PubMed Web of Science ®Google Scholar
• Li S, Meng W, Guan Z, et al. The hypoxia-related signaling pathways of vasculogenic mimicry in tumor treatment. Biomed Pharmacother. 2016;80:127–135.
   PubMed Web of Science ®Google Scholar
• Du J, Sun B, Zhao X, et al. Hypoxia promotes vasculogenic mimicry formation by inducing epithelial-mesenchymal transition in ovarian carcinoma. Gynecol Oncol. 2014;133:575–583.
   PubMed Web of Science ®Google Scholar
• Luo Q, Wang J, Zhao W, et al. Vasculogenic mimicry in carcinogenesis and clinical applications. J Hematol Oncol. 2020;13:19.
   PubMed Web of Science ®Google Scholar
• Wei L, Wang X, Lv L, et al. The emerging role of noncoding RNAs in colorectal cancer chemoresistance. Cell Oncol (Dordr). 2019;42:757–768.
   PubMed Web of Science ®Google Scholar
• Vodenkova S, Buchler T, Cervena K, et al. 5-fluorouracil and other fluoropyrimidines in colorectal cancer past, present and future. Pharmacol Ther. 2020;206:107447.
   PubMed Web of Science ®Google Scholar
• Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721–732.
   PubMed Web of Science ®Google Scholar
• Erin N, Grahovac J, Brozovic A, et al. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 2020;53:100715.
   PubMed Web of Science ®Google Scholar
• Saxena K, Jolly MK, Balamurugan K. Hypoxia, partial EMT and collective migration: emerging culprits in metastasis. Transl Oncol. 2020;13:100845.
   PubMed Web of Science ®Google Scholar
• Tang C, Liu T, Wang K, et al. Transcriptional regulation of FoxM1 by HIF-1alpha mediates hypoxia-induced EMT in prostate cancer. Oncol Rep. 2019;42:1307–1318.
   PubMed Web of Science ®Google Scholar
• Ning M, Qin S, Tian J, et al. LncRNA AFAP-AS1 promotes anaplastic thyroid cancer progression by sponging miR-155-5p through ETS1/ERK pathway. Bioengineered. 2021;12:1543–1554.
   PubMed Web of Science ®Google Scholar
• Qian J, Garg A, Li F, et al. lncRNA LUNAR1 accelerates colorectal cancer progression by targeting the miR4953p/MYCBP axis. Int J Oncol. 2020;57:1157–1168.
   PubMed Web of Science ®Google Scholar
• Li H, Wang D, Yi B, et al. SUMOylation of IGF2BP2 promotes vasculogenic mimicry of glioma via regulating OIP5-AS1/miR-495-3p axis. Int J Biol Sci. 2021;17:2912–2930.
   PubMed Web of Science ®Google Scholar